With continuous investigator initiated National Institutes of Health research grant funding since 1986, Dr. Dodd has authored and presented more than 200 papers to professional conferences and symposia, contributed to dozens of books and is frequently invited to give the keynote address to professional nursing and oncology associations. Her research interests focus on randomized controlled trials to prevent and manage the side effects of cancer treatment, and decreasing treatment-related morbidity with cancer patients and their families.

She serves on numerous academic review committees, is a reviewer for a dozen professional journals including Cancer Investigation and the Journal of Clinical Oncology. She has served on more than 30 national oversight committees including serving as site visitor for the National Cancer Institute, grant reviewer for the National Institutes of Health, and as a member of the scientific advisory committee for Michigan State University Cancer Center.

Among her many honors, she was elected to be a fellow in the American Academy of Nursing in 1986. She received the Oncology Nursing Society/Chiron Excellence of Scholarship and Consistency of Contribution to the Oncology Nursing Literature (Career Award), and in 1997 won the Oncology Nursing Society/Bristol-Meyers Distinguished Research award.

Dr. Dodd is a member of numerous professional organizations including the American Nurses Association and the Oncology Nursing Society.

Among recent honors awarded, in 2000 she received the Oncology Nursing Society/Chiron Excellence of Scholarship and Consistency of Contribution to the Oncology Nursing Literature (Career Award). She was invited to present at the State-of-the-Science Conference on Symptom Management in Cancer: Pain, Depression, and Fatigue, sponsored by the National Cancer Institute and the Office of Medical Applications of Research of the National Institutes of Health (and other sponsors) at the NIH Campus in 2002, and in 2003 was awarded the Sharon A. Lamb Endowed Chair in Nursing. In her role as director of the Center for Symptom Management, she was chosen as the recipient of the 2005 Sigma Theta Tau/Baxter International Foundation’s Episteme Award. This award is presented to a person or team for highly significant research and acknowledges a major breakthrough in nursing knowledge development that has resulted in a significant and recognizable benefit to the public. Most recently Dr. Dodd was awarded the Robert Tiffany Lectureship by the International Society of Nurses in Cancer Care giv

Brian G. M. Durie, M.D. - Multiple Myeloma
Chairman of the Board, Scientific Director of the International Myeloma Foundation; Senior Advisor, Hematologic Malignancies, Salick Health Care, Inc.

Dr. Durie is chairman and scientific director of the International Myeloma Foundation based in Los Angeles, California, where he maintains a private hematology, oncology practice specializing in myeloma and related diseases. Dr. Durie is a staff member in the Medical Affairs and Cancer Research Departments at Cedars-Sinai in Los Angeles, and is also chairman of the Myeloma, Hematologic Malignancy and Cancer Basic Science Liaison Committees for Salick Health Care, Inc. Research Department.

Dr. Durie’s research interests focus on evaluation and management of stealth virus infection in patients with multiple myeloma and related diseases. A high percentage of patients with active myeloma have positive stealth virus cultures, which are frequently associated with neurologic sequelae in patients as well as other family members. More detailed studies in myeloma and other cancers are warranted. Innovative treatment strategies including antiviral (e.g. gancyclovir) and antibiotic (e.g. Biaxin), approaches as well as thalidomide have proven beneficial.

Dr. Durie holds numerous honors and has been the recipient of many awards; among them he was a Leukemia Society of America Scholar, and the US Hematologic Research Foundation Annual Awardee in 1991. He is listed in Marquis "Who's Who in America" and "The Best Doctors in America."

He has written over 250 research papers, over 128 myeloma research papers, as well as numerous book chapters and has published two books. His multi-author myeloma text was republished in a 2nd edition in 2002. He is also the international patent holder for scintillation autoradiography

William Ellis, M.D. Emeritus Board Member - Bladder Cancer, Kidney Cancer
Associate Professor of Urology, University of Washington School of Medicine

Dr. Ellis received his M.D. from Johns Hopkins University School of Medicine and did his general surgery and urology training at the Northwestern University Medical School in Chicago. He has held associate and assistant professor of urology appointments at the University of Washington since 1991. Ellis has been board certified by the American Board of Urology since 1993. His primary clinical research focus is prostate and bladder tumors, as well as understanding how patients make prostate cancer treatment decisions. His basic science research includes development of animal models of prostate cancer, studies of prostate cancer dissemination and metastases, and hormonal manipulation of prostate cancer. Ellis also serves as principal investigator for the national Prostate Cancer Prevention Trial and the Prostate Cancer Intervention versus Observation Trial. He has co-authored more than 50 journal papers and abstracts and made nearly 70 scientific presentations. He has also contributed to more than eight books on genitourinary cancer. He is a member of the American Urological Association, the Society of Urologic Oncology, the Northwest Urological Association, the Southwest Oncology Group and the Western Section American Urological Oncology.

Stephen Eulau, M.D. - Breast Cancer
Swedish Cancer Institute-Tumor Institute Radiation Oncology Group; Director of Education for the Seattle Prostate Institute

Inspired by the pioneering work of the Seattle Prostate Institute, Dr. Eulau became active in transperineal prostate implantation in the mid 1990’s, establishing the ultrasound guided prostate implant program at Stanford University. Given the opportunity to work shoulder-to-shoulder with Drs. Grimm, Sylvester, and Blasko, he joined the Seattle group in 1998 and has been active in research and teaching at the Seattle Prostate Institute since then.

His investigational work has been presented across the country at national meetings. He has guided the establishment of prostate implant programs in other sites across the western United States, and physicians continue to request consultations on challenging cases. Dr. Eulau is unique in that his expertise spans both permanent seed implantation as well as temporary high dose rate (HDR) implantation. He and HDR pioneer, Timothy Mate, M.D. have been involved in refining this technique as it is practiced at centers of excellence throughout the country.

Exemplary clinical care built on a "one patient at a time" philosophy is the core of Dr. Eulau’s practice. His goal is to optimize patient outcome in terms of cancer free survival, as well as quality of life, by individualizing treatment decisions.

Dr. Eulau serves as the director of education for the Seattle Prostate Institute. Each year the institute trains scores of physicians in the techniques of prostate seed implantation.

Clinical Interests

• Breast Cancer – Mammosite, APBI, NSABP B-39 Trial
• Prostate Cancer – HDR and permanent seed implantation, IMRT
• Gastrointestinal Cancers – 3D and IMRT planning with PET/CT fusion.
• Combined modality care.

Education and Certification

• Medical School: University of California, Davis, CA
• Residency: Albert Einstein Medical Center, PA; Stanford University, CA
• B.A. Harvard University

Board Certification(s): Radiation Oncology
Additional Qualifications Internship: University of Pennsylvania, PA

Eli Glatstein, M.D. - All Cancer Tools
Professor and Vice Chair, Department of Radiation Oncology and Clinical Director, Radiation Oncology, University of Pennsylvania Medical Center

Dr. Glatstein is highly regarded among his colleagues in radiation oncology. As vice chair and the clinical director of the Department of Radiation Oncology, Dr. Glatstein is responsible for training all radiation oncology students, as well as directing the lecture program for radiation oncology faculty and staff at the University of Pennsylvania. His 35-year career includes faculty, hospital and administrative appointments at Stanford University, The National Cancer Institute, and the University of Texas Southwestern Medical Center. He also has worked as a consultant to the Lawrence Radiation Laboratory at Berkeley, Calif.

He has served on numerous national committees including the National Cancer Institute's Investigational Review Board, the PDQ Editorial Board, the 1995 search committee for NCI director, and as the NCI's representative to the American Joint Committee on Cancer. He also worked on the Radiation Safety Committee of the National Institutes of Health, the Brookhaven National Laboratory Radiation Therapy committee, and the Presidential Advisory Committee on Human Radiation Experiments, among many others.

Dr. Glatstein also has served on the editorial boards of Clinical Cancer Research, Cancer Research, Journal of the National Cancer Institute and Radiotherapy and Oncology, and currently serves as senior editor for both the International Journal of Radiation Oncology, Biology and Physics, and Clinical Radiation Oncology.

He is a member of the American Society of Clinical Oncology, American Society of Therapeutic Radiation Oncology, American College of Radiology and the American College of Radiation Oncology, and is certified by the American Board of Radiology.

---

Helmuth Goepfert, M.D., Emeritus Board Member - Head and Neck Cancers
Professor of Surgery and Chairman, Department of Head and Neck Surgery, University of Texas M.D. Anderson Cancer Center

Dr. Goepfert, an expert in head and neck surgery, is a professor of surgery and chairman of the Department of Head and Neck Surgery at the University of Texas M.D. Anderson Cancer Center, where he also serves as the M.G. & Lillie A. Johnson Chair for Cancer Treatment and Research. Dr. Goepfert is also the adjunct professor of Otolaryngology in the Bobby R. Alford Department of Otorhinolaryngology and Communicative Sciences at the Baylor College of Medicine in Houston, Texas. From 1984 to 1985, he acted as chairman of the Research Committee of the M.D. Anderson Cancer Center, where his membership included the Patient Care Committee and the Patient Education Committee. Currently, he is chair of the Surgical Materials Use Evaluation Subcommittee and the medical liaison for head and neck surgery in the International Patient Center at the M.D. Anderson Cancer Center. He holds memberships in the American Society for Head and Neck Surgery and the Task Force on Head and Neck Cancers, among others. Dr. Goepfert has held positions as the chief editor of Head & Neck as well as the editor of the Archives of Otolarynology and of The Cancer Bulletin. At the present time, he serves on the editorial boards of the Archives of Otolarynology, Annals of Surgical Oncology, Head & Neck, and the Journal of Surgical Oncology. His many awards and distinctions include the Charles LeMaistre Outstanding Achievement Award in Cancer, from the M.D. Anderson Cancer Center (1998), and the Distinguished Surgeon Award, from the Association of Operation Room Nurses of Greater Houston and the AORN Foundation (1999). Dr. Goepfert was a guest of honor at the Annual Meeting of the American Head and Neck Society (1999). He has extensive teaching experience and has published widely, with more than 200 articles published in reference journals and 50 published books and chapters.

---

Dr. Richard J. Gralla, M.D. - Non-small Cell Lung Cancer, Small Cell Lung Cancer
President, New York Lung Cancer Alliance

Dr. Gralla was recently named president of the New York Lung Cancer Alliance in New York. Prior to accepting that position, he was professor of medicine, Columbia University, also in New York. He has also been the chief of thoracic oncology at Memorial Sloan-Kettering Cancer Center (New York), and director of the Ochsner Cancer Institute in New Orleans, Louisiana.

Dr. Gralla received his medical degree from the University of Virginia in Charlottesville. He completed a fellowship in medical oncology and was a National Cancer Institute fellow in clinical research at Memorial Sloan-Kettering Cancer Center.

Dr. Gralla is the author or co-author of over 200 articles and book chapters, and his work has been published in journals such as the New England Journal of Medicine, Annals of Internal Medicine, Journal of Clinical Oncology, Cancer, and Cancer Research. Dr. Gralla serves on the editorial boards of Cancer, Lung Cancer, and Supportive Care in Cancer. He is a member of the American Society of Clinical Oncology, the American Association for Cancer Research, and the International Association for the Study of Lung Cancer. Dr. Gralla is president of the Multinational Association of Supportive Care in Cancer.

---

Peter Grimm, D.O. - Prostate Cancer, Bladder Cancer
Director of Research Seattle Prostate Institute Swedish Medical Center

Dr. Grimm is a practicing radiation oncologist who heads the Seattle Prostate Institute at the Swedish Medical Center. He is the CEO of ProQura, a company dedicated to insuring the quality of prostate brachytherapy. He has been board certified by the American College of Radiology-Therapeutics since 1984. He was recently appointed by the Health Secretary Tommy Thompson, to the Medicare Practicing Physicians Advisory Council in Washington, D.C. He is former adjunct assistant professor of radiation oncology at the University of California at Los Angeles Department of Radiation Oncology.

Dr. Grimm was instrumental in establishing the first transperineal prostate implantation program in the United States and has since devoted considerable effort to bringing about improvements in both the technical aspects of the implant procedure and the standards of practice among physicians and other clinical staff providing implantation services. He also developed the Seattle Prostate Institute Education program, which has trained thousands of physicians to perform seed implantation. He has authored and co-authored more than two dozen papers and has six U.S. patents in the field of brachytherapy. He was the principal developer of the I-125 Rapid Strand and the Pd 103 and I-125 Source Link Spacers designed to eliminate movement of implanted seeds inside the prostate. He also has patents for an advanced design of the needles used in implant procedures and ultrasound detection of the pubic arch.

His current research interests include selection issues for Brachytherapy, the preservation of nerve function and maintenance of potency following implantation, and techniques to minimize prostate movement during the implant procedure.

Dr. Grimm obtained his medical degree at the Chicago College of Osteopathic Medicine, and served as chief resident at the UCLA Department of Radiation Oncology. He is a member of, the King County Medical Society, the American Society for Therapeutic Radiology and Oncology, the Washington Osteopathic Medical Association, the Puget Sound Oncology Consortium, and is past-president of the Washington State Radiological Society.

---

Daniel F. Hayes, M.D. - Breast Cancer
Clinical Director of the Breast Cancer Program at the Vincent T. Lombardi Cancer Center
Associate Professor of Medicine, Georgetown University Medical Center

Dr. Daniel Fleming Hayes is the director of the Breast Oncology Program at the University of Michigan Cancer Center, where he is also a professor of medicine. The University of Michigan is a federally designated Comprehensive Cancer Center that has placed a particular emphasis on cancer research that translates laboratory findings to the clinic.

Dr. Hayes has been influential in both clinical and laboratory studies of the diagnosis and treatment of breast cancer. With his long-time colleague, Dr. Donald Kufe, Dr. Hayes published the first reports concerning the development of the CA15-3 blood test, which is currently used world-wide to evaluate patients with breast cancer. He has become an internationally recognized leader in the use of this and other tumor markers, such as HER-2, specifically for breast but also for other cancers. He is widely considered to be an expert in the field of clinical research of breast cancer, especially in regards to new hormonal and chemotherapeutic treatments. He also lectures and publishes extensively regarding the management of patients with breast cancer.

He received his M.D. from the Indiana University School of Medicine in 1979, followed by a residency in internal medicine at the University of Texas Health Science Center at Dallas, Texas (Parkland Memorial and affiliated hospitals). He served a fellowship in medical oncology from 1982-1985 at Harvard’s Dana Farber Cancer Institute in Boston, where he subsequently distinguished himself on the faculty in regards to breast cancer research and care. In 1992, he assumed the role as the Medical Director of the Breast Evaluation Center at DFCI

---

I. Craig Henderson, M.D. - Breast Cancer
Adjunct Professor of Medicine, University of California, San Francisco

Dr. Henderson is a board-certified internist and medical oncologist, and has carried out extensive research on the topic of breast cancer. Besides teaching at the University of California, San Francisco, Dr. Henderson is an attending physician at the university’s medical center, as well as at Moffitt-Long Hospital, Mount Zion Hospital, and UCSF/Mount Zion Cancer Center.

From 1992 to 1995, he served as Chief of the Division of Medical Oncology for the Moffitt-Long-Mt.Zion Hospitals in San Francisco. In 1980, he founded the Breast Evaluation Center at the Dana-Farber Cancer Institute, serving as its director until 1992. From 1974 to 1991, Dr. Henderson directed the breast cancer program at the Dana-Farber Cancer Institute where he has also served as a Principal Investigator on clinical trials.

In 1995, while continuing at UCSF as an adjunct professor, Dr. Henderson became CEO and Chairman of Sequus biopharmaceuticals where he lead the development program for the anticancer drug, Doxil. In 2000 he began working with Michael Weiss in the creation of a new biotechnology company, Access Oncology, that was focused entirely on the development of novel anticancer drugs. Access Oncology was merged with Keryx Biopharmaceuticals in 2004. Today Dr. Henderson is President of Keryx Biopharmaceuticals; he continues to see breast cancer patients at UCSF and serves on the steering committee of the UCSF breast cancer SPORE.

Other prestigious positions he has held are: Chairman of the Committee on Metastatic Breast Cancer; Principal Investigator of an Intergroup trial that randomized 3,170 women with early breast cancer; Founder and Director of the Bay Area Breast Cancer Translational Research; and Chairman of the Cancer and Leukemia Group B (CALGB) Breast Core Committee. Dr. Henderson has also taught the Harvard University Medical School postgraduate course, in the Cancer Medicine division. He chaired the Oncologic Drugs Advisory Committee of the FDA from 1989-1992, and served on the Blue Cross Blue Shield National Association Medical Advisory Panel, which reviews medical technology assessments, since 1991 and became a member of the Medicare Coverage Advisory Committee in 2007.

He has authored more than 200 journal articles and books primarily on the topic of breast cancer and received awards three years in a row from the Breast Cancer Research Foundation (1995 to 1998). He has been a member of the American Cancer Society’s National Task Force on Breast Cancer Control since 1988.

---

Celestia (Tia) S. Higano, M.D. - Prostate Cancer
Associate Professor, Department of Urology and the Department of Medicine University of Washington School of Medicine

Celestia (Tia) S. Higano, MD is Associate Professor of Medicine and Urology at the University of Washington and Fred Hutchinson Cancer Research Center. She received her M.D. from University of Massachusetts Medical School and completed her residency in internal medicine at the Mayo Graduate School of Medicine and fellowship in medical oncology at the Fred Hutchinson Cancer Research Center/University of Washington.

She is head of the Prostate Cancer Clinical Research Program at the University of Washington located at the Seattle Cancer Care Alliance and is one of ten principal investigators participating in the Department of Defense Prostate Cancer Clinical Trials Consortium. She is the Director of the Clinical Core of the Pacific Northwest Prostate Cancer SPORE grant held by the Fred Hutchinson Cancer Center.

As a member of the Southwest Oncology Group, she serves as the Oncology Discipline Chair of the Genitourinary Committee. Dr. Higano's research focuses on studying the effects of intermittent androgen deprivation in men with non-metastatic prostate cancer to inform the design of prevention and treatment strategies.

Her research has been published in journals such as Journal of Clinical Oncology, Cancer, Cancer Clinical Research, Journal of Urology, Urology, Hematology/Oncology Clinics of North America, Urologic Clinics of North America, Blood. She has also authored numerous book chapters, reviews, monographs and edited American Cancer Society's Complete Guide to Prostate Cancer.

She is a member of the American Society of Clinical Oncology, the American Urological Association, Society of Urologic Oncology

---

Chris Holsinger, M.D. - Head and Neck Cancers
Assistant Professor, Department of Head and Neck Surgery, at The University of Texas M. D. Anderson Cancer Center in Houston, Texas

Dr. Holsinger received his medical degree from Vanderbilt School of Medicine in Nashville, Tennessee. He completed his internship and residency at Baylor College of Medicine in Houston and his Fellowship in head and neck surgical oncology at The University of Texas M. D. Anderson Cancer Center.

Board-certified by the American Board of Otolaryngology, Dr. Holsinger is a member of several medical societies including the American College of Surgeons, the American Society of Clinical Oncology (ASCO), AACR, AAAS, The Triological Society, and the American Head and Neck Society.

Dr. Holsinger has authored or co-authored numerous articles and abstracts, which have appeared in publications such as the Journal of the American College of Surgeons, the Journal of Clinical Oncology, Clinical Cancer Research, Head & Neck, Laryngoscope, and the Archives of Otolaryngology—Head and Neck Surgery.

He maintains an active translational research laboratory and conducts research in the molecular determinants of resistance to induction chemotherapy and in the prediction of metastasis in head and neck cancer.

In 2003, he was awarded Fulbright Scholarhip to study surgery at the University of Paris with Professor Ollivier Laccourreye and with Professor Wolfang Steiner at the Georg-August University in Göttingen.

Research Interests

• Genomic and Proteomic Assessment of Survival, Metastasis, and Response to therapy of head and neck cancer
• Clinical trials research
• Laryngeal conservation surgery:
  • supracricoid partial laryngectomy
  • transoral laser microsurgery of the head and neck
  • transoral robotic surgery
• Regional metastasis in thyroid malignancy
• Management of locally invasive thyroid cancer

Fellowships
Head & Neck Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, 2001-2003

---

Richard T. Hoppe, M.D., F.A.C.R. - All Cancer Tools
Henry S. Kaplan - Harry Lebeson Professor and Chairman Department of Radiation Oncology, Stanford University School of Medicine

Dr. Hoppe has chaired the Department of Radiation Oncology at Stanford University School of Medicine since 1994. He is also vice chair of the Department of Radiation Oncology at Santa Clara Valley Medical Center and a member of the Board of Stanford University Hospital.

His research interests include: Hodgkin's disease, the non-Hodgkin's lymphomas, mycosis fungoides, radiation immunosuppression (total lymphoid irradiation), total body irradiation, and bone marrow transplantation. He has co-authored more than 200 research articles, and contributed to more than 75 books on radiation oncology. He is a co-editor of the textbook Hodgkin's Disease, published in 1999.

Dr. Hoppe completed his undergraduate and doctor of medicine degrees at Cornell University in New York. He interned at Cornell Cooperating Hospitals-North Shore Hospital and Memorial Hospital in New York, and completed a postdoctoral fellowship in radiation therapy and cancer biology research at Stanford University, Stanford, Calif.

Dr. Hoppe serves on the editorial boards of the International Journal of Radiation Oncology, Biology and Physics, Oncology Times, Advanced Medical Publishing, The Cancer Journal of the Scientific American among others. He is board certified by the American Board of Radiology in Therapeutic Radiology.

His numerous academic and public honors include Fellowship in the American College of Radiology; The E. Richard King Memorial Lecture of the Medical College of Virginia; Best Cancer Specialists in the US, Good Housekeeping; The Best Doctors in America, American Health; and The Best Doctors in America: Pacific Region. He has delivered the Radiation Oncology Oration at the Annual Scientific Meeting of the Radiological Society of North America, the Vera Peters Lecture at the Princess Margaret Hospital, and he received the Janeway Award from the American Radium Society. Dr. Hoppe is a former President and Chairman of the Board of the American Society for Therapeutic Radiology and Oncology, and he is a member of the American College of Radiology and the American Society of Clinical Oncology. He serves as a Trustee of the American Board of Radiology.

---

Merrill Stephen Kies, M.D. Member Emeritus, Medical Editorial Board - Head and Neck Cancers, Non-small Cell Lung Cancer, Small Cell Lung Cancer
Professor of Medicine, Department of Thoracic/Head and Neck Medical Oncology,
University of Texas M. D. Anderson Cancer Center, Houston, Texas

Over the past 20 years Dr. Kies has contributed to improved treatments for head and neck, and lung cancers. He has authored and co-authored more than 200 research studies and abstracts, and more than a dozen book chapters on cancer treatment. His current research focuses on improving the effectiveness of multimodal treatment regimens for these cancers.

He is currently a fellow of the American College of Physicians, and a member of the American Association for Cancer Research, the American Society of Clinical Oncology, the Society of Head and Neck Surgeons, and the International Association for the Study of Lung Cancer.

Well regarded by peers, Dr. Kies frequently contributes to national and international conferences aimed at improving oncology care. Most recently, he participated in the Ninth World Conference on Lung Cancer in Tokyo, Japan and the 2000 American Society of Clinical Oncology Clinical Practice Forum in Orlando, Fla.

Dr. Kies also serves as a reviewer for several cancer research journals including Cancer, Clinical Cancer Research and the Journal of the National Cancer Institute. He is on the editorial board of the Journal of Clinical Oncology.

A graduate of Loyola University of Chicago where he earned his medical doctorate in 1973, Dr. Kies trained in internal medicine at Walter Reed General Hospital in Washington, D.C. He completed a hematology/oncology fellowship at the Brooke Army Medical Center in Texas. He is certified by the American Board of Internal Medicine with subspecialty in Medical Oncology.

---

Krishna Komanduri, M.D. - All Cancer Tools
Associate Professor of Medicine, Department of Stem Cell Transplantation and Cellular Therapy, M.D. Anderson Cancer Center; Director of the fellowship program in Bone Marrow Transplantation, and Associate Director of the Hematology/Oncology Fellowship Program at M.D. Anderson

Dr. Komanduri grew up in Minneapolis, Minnesota. He attended the Massachusetts Institute of Technology as a National Merit Scholar and received the Bachelor of Science in Biology in 1987. He attended the University of Minnesota Medical School and received his M.D. degree in 1991. He received the Minnesota Medical Foundation Outstanding Student Award and the University of Minnesota President's Student Leadership and Service Award.

He completed a residency in Internal Medicine at the University of California, Los Angeles Center for Health Sciences in 1994. He then completed fellowship training in Hematology and Medical Oncology at the University of California, San Francisco in 1997. He also completed a postdoctoral laboratory fellowship in immunology at the Gladstone Institute of Virology and Immunology and was awarded an Amgen Research Fellowship in Medical Oncology and a University of California-wide AIDS Research Program Fellowship.

From 1997-1999 he served as Assistant Adjunct Professor of Medicine at UCSF and served as an Attending Physician in Hematology and Bone Marrow Transplantation. Dr. Komanduri joined the faculty at the University of Texas M.D. Anderson Cancer Center in the Section of Transplantation Immunology in the Dept. of Blood and Marrow Transplantation as an Assistant Professor and Assistant Internist in 1999.

Dr. Komanduri is a diplomate of the American Board of Internal Medicine in the fields of Internal Medicine, Hematology, and Medical Oncology.

Dr. Komanduri's laboratory focuses on the study of immune reconstitution and cellular immunotherapy following bone marrow transplantation. His clinical interests include hematologic malignancies and bone marrow transplantation.

---

Robert A. Kyle, M.D. - Multiple Myeloma
Professor of Medicine and Laboratory Medicine, Mayo Medical School

Dr. Kyle received his medical degree from Northwestern University Medical School in Chicago. He completed an internship at Evanston Hospital in Evanston, Ill., and his residency in internal medicine at the Mayo Clinic in Rochester, Minn. He received a research fellowship in hematology at Tufts University School of Medicine in Boston. He is board certified in internal medicine and hematology. Dr. Kyle is a professor of medicine and laboratory medicine at Mayo Medical School.

His research interest focus on monoclonal gammopathies including multiple myeloma, Waldenstrom's macroglobulinemia, primary systemic amyloidosis, solitary plasmacytoma, extramedullary plasmacytoma, POEMS syndrome, smoldering multiple myeloma and monoclonal gammopathy of undetermined significance.

He served as the William H. Donner professor of medicine at Mayo Medical School. He was the section head of the division of hematology and subsequently, the chairman of the division of hematology at Mayo Clinic. He has been chairman of the Myeloma Committee of the Eastern Cooperative Oncology Group. He is currently on the board of directors and is chairman of the scientific advisory board of the International Myeloma Foundation. He also serves as chairman of the scientific advisors board of scientific advisors of the International Waldenström's Macroglobulinemia Foundation. He has been secretary-general of the International Society of Hematology, and is president of the International Society of Amyloidosis. Dr. Kyle has edited numerous texts and has published more than 1,500 journal articles, book chapters and abstracts.

---

Paul Lange, M.D., Member Emeritus, Medical Editorial Board - Bladder Cancer
Chairman of Urology, University of Washington Medical Center

Dr. Lange is a recognized leader in the field of prostate cancer. Currently, he is Professor and Chairman of the Department of Urology and Director of the Tumor Immunology Urology Laboratory at the University of Washington Medical Center in Seattle, WA. From 1985 to 1988 he served as Professor and Vice Chairman of the Department of Urology, and Professor of Urology from 1981-1985 at the University of Minnesota. Dr. Lange has received several awards in scientific forums such as the American Urological Association and has authored or co-authored hundreds of peer-reviewed urological articles. He has served on numerous editorial boards including the New England Journal of Medicine and currently serves in that capacity for Urology and Contemporary Urology. He holds active affiliations with several professional and honorary societies and is internationally recognized for his clinical and experimental work in a variety of genitourinary cancers including prostate, testis, bladder, and kidney.

---

Richard A. Larson, M.D., Emeritus Board Member - Adult Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia, Adult Acute Myelogenous Leukemia
Professor of Medicine, Hematology/Oncology Section; Director Hematologic Malignancies Program, Pritzker School of Medicine, University of Chicago Cancer Research Center

Dr. Larson's 20 years specializing in hematology and oncology spans a period of substantial advances in the treatment of hematological cancers including leukemias. During that time, Dr. Larson contributed to many clinical studies leading to improved treatment and outcomes of leukemia patients. His current research interests include clinical trials using new chemotherapy agents and stem cell transplantation, determining factors crucial to treatment response and the etiology of therapy-related leukemias.

Dr. Larson graduated from Dartmouth College, New Hampshire, and from King's College, University of Cambridge, England and earned his medical doctor degree from Stanford University School of Medicine. He served his residency and fellowship in hematology and oncology at the University of Chicago. He also was selected as a fellow of the Leukemia Society of America and received the Clinical Oncology Career Development Award of the American Cancer Society.

He is board certified as a diplomate of the National Board of Medical Examiners, and the American Board of Internal Medicine, including diplomate status in hematology and oncology.

Dr. Larson has served on regional and national committees as chair of the Medical Advisory Board for the Leukemia Research Foundation, chair of the Leukemia Committee of the Cancer and Leukemia Group B, and as a member of the subspecialty board on hematology for the American Board of Internal Medicine.

He also is a member of several medical organizations including the American College of Physicians, American Society of Hematology, American Society of Clinical Oncology and the American Association for Cancer Research.

---

Maurie Markman, M.D. - Ovarian Cancer, Uterine Cancer, Cervical Cancer
First Vice President for Clinical Research, University of Texas M. D. Anderson Cancer Center

Dr. Markman took on the responsibilities of the newly created office of cllinical research to support clinical researchers within and outside M.D. Anderson's Cancer Center as part of the center's comprehensive effort to enhance the institution’s internationally-recognized clinical research program and to better serve the needs of its 600 clinical investigators.

Dr. Markman previously served as director of the renowned Cleveland Clinic's Taussig Cancer Center, where he also served as chair of the clinic's department of hematology and oncology. Nationally, he currently serves as chair of the medical oncology committee of Gynecologic Oncology Group.

Over his nearly 30-year career, Dr. Markman has focused his laboratory and clinical research on gynecologic malignancies and experimental therapies. He has co-authored more than 150 research papers, contributed to more than 60 books on cancer and given more than 600 scientific presentations. He is editor-in-chief of Current Oncology Reports, and has served as editor of Oncology Digest, and associate editor of both the Cleveland Clinic Journal of Medicine and Clinical Cancer Research and serves as a reviewer for numerous scientific journals including The Lancet, Cancer Research, Cancer, and the Journal of the National Cancer Institute.

Dr. Markman graduated from the University of Southern California in 1970 and earned a M.D. from New York University School of Medicine, New York in 1974 and added a masters degree in Health Policy and Management in 1989. He trained at Bellevue Hospital-New York University Medical Center, Johns Hopkins University Medical Center in Baltimore, and the National Cancer Institute, Bethesda. He is a fellow of the American College of Physicians.

He is board certified in internal medicine, medical oncology and hematology. Dr. Markman is a member of numerous medical associations including the American College of Physicians, the American Society of Clinical Oncology and the American Association for Cancer Research. His many honors include membership in the Alpha Omega Alpha Medical Honor Society and the Phi Beta Kappa society and is regularly listed among "The Best Doctors" survey of physicians

---

Vivek K. Mehta, M.D. - Colorectal Cancer
Radiation Oncology, Swedish Cancer Institute,

Dr. Mehta is actively involved in designing and developing clinical research studies at the Swedish Cancer Institute in Seattle, WA and through national research organizations, including the Southwestern Oncology Group (SWOG). He has written extensively about the use of concurrent chemotherapy and radiation in the management of malignancy and presented findings at national and international meetings.

His clinical interests include balloon catheter based breast brachytherapy, gamma knife radiosurgery, intensity modulated radiotherapy, stereotactic radiosurgery, targeted radiolabeled antibodies, three-dimensional conformal radiotherapy. He is also interested in assisting patients understand the wide variety of treatment options available for nearly every patient. He believes it is important to spend much time as is needed to help patients weigh the benefits and risks to any particular approach. He believes in flexibility and tailoring treatment to the individual situation, which sometimes means using techniques perfected over the years and at other times incorporating newer more investigational or "cutting-edge" approaches. The key is open and honest communication. The goals of treatment, whether it is going for "cure" or maximizing "quality of life," should be openly discussed and rediscussed as the need arises.

Dr. Mehta earned his doctor of medicine degree at the University of Washington, WA, served his residency at Stanford University in Palo Alto, CA and his internship at Good Samaritan in Portland OR. He is board certified in Therapeutic Radiology.

His many honors include Seattle's Top Doctors List, Seattle Magazine, August 2004; the Malcolm A. Bagshaw Radiation Oncology Resident Award, 2001; the ASCO Resident/Fellow Research Award, 2001; the RSNA-Roentgen Resident/Fellow Research Award, 2000.

---

Craig Nichols, M.D. - Testicular Cancer
Medical Director of Lymphoma and Testicular Cancer Research at the Earle A. Chiles Research Institute in Portland, Oregon

Dr. Nichols is a world-renowned physician and researcher with special experience and expertise in treating patients with Hodgkin's disease, non-Hodgkin's lymphoma and testicular cancer. He also serves as Director of Clinical Program Development at Providence Cancer Center, assembling multidisciplinary teams of researchers, physicians, nurses and support people to improve outcomes and the standard of care for other cancers. Highly specialized clinical expertise, groundbreaking research, and patient outreach and education are the hallmarks of these programs.

Since 1998 until he joined the Providence Cancer Center in 2007, Dr. Nichols was Professor of Medicine, the DeArmond Chair of Clinical Cancer Research, the head of the Division of Hematology and Medical Oncology at Oregon Health & Science University and Associate Director of the Cancer Institute's Clinical Research program. In 1978, Dr. Nichols received his medical degree from OHSU. After completing his Internal Medicine residency in New Orleans, he received fellowship training in hematology and oncology at Indiana University. He spent 15 years at Indiana University and obtained the rank of Professor of Medicine with tenure there in 1996.

---

Robert F. Ozols, M.D., Ph.D. - Ovarian Cancer, Uterine Cancer, Cervical Cancer
Senior Vice President for Medical Science, Fox Chase Cancer Center, Philadelphia, PA; Director, Fox Chase Cancer Center/Temple University Cancer Program, Philadelphia, PA; Medical Director, Hospital of the Fox Chase Cancer Center; Professor of Medicine, Temple University

As senior vice president for medical science at Fox Chase Cancer Center, Dr. Ozols oversees all the center's patient care, clinical research, and medical science laboratory research. Internationally recognized for his expertise in ovarian cancer, Ozols' research focuses on how cancer cells develop resistance to anticancer drugs and on developing strategies for overcoming drug resistance, which often occurs in ovarian cancer.

Ozols developed new clinical approaches to treating patients with ovarian cancer with high-dose chemotherapy, using paclitaxel and carboplatin combinations, and pharmacologic techniques to reverse drug resistance. He is principal investigator of a National Cancer Institute Specialized Program of Research Excellence (SPORE) grant for ovarian cancer, and principal investigator at Fox Chase for the Gynecologic Oncology Group.

Ozols received the 25th Annual Bristol-Myers Squibb Award for Distinguished Achievement in Cancer Research (shared with Robert C. Young, M.D.), the 1990 Cancer Research Award from the Milken Family Medical Foundation, and the Ninth Claude Jacquillat Award in Clinical Research. He received the Public Health Service Outstanding Unit Award in 1984 and 1988 as head of the Experimental Therapeutics Section of the National Cancer Institute's Medicine Branch. He received the Commendation Medal in 1987 from the federal Public Health Service for developing a new chemotherapy regimen for testicular cancer.

The author of many scientific publications, Ozols also serves on numerous editorial boards, including those of the International Journal of Gynecologic Cancer, International Journal of Oncology, Cancer Research, Cancer Investigation, Journal of Experimental Therapeutics and Oncology, and Clinical Cancer Research.

He has served on the Oncologic Drugs Advisory Committee of the Food and Drug Administration (1992-1996). He is a member of several professional organizations, including the American Society of Clinical Investigation (ASCI), American Association for Cancer Research (AACR), and American Society of Clinical Oncology (ASCO), served as Vice President of the International Gynecologic Cancer Society (IGCS) (2005-2006). He has also served on the Board of Directors of ASCO (2000-2003), and the American Association of Cancer Institutes (2001-2002).

Born in Latvia in 1944, Ozols earned his bachelor's degree in chemistry from the University of Rochester, Rochester, NY and his Ph.D. and M.D. from the same university in 1971 and 1974. He completed his medical training at Dartmouth-Hitchcock Medical Center in Hanover, New Hampshire, and medical oncology fellowship at the National Cancer Institute. He is certified in Internal Medicine and Medical Oncology by the American Board of Internal Medicine.

---

Edith Perez, M.D., Emeritus Board Member - Breast Cancer
Associate Professor of Medicine, Mayo Medical School, Jacksonville, Florida
Director, Clinical Investigations, Division of Hematology/Oncology, Mayo Clinic Jacksonville, Florida
Director, Breast Cancer Program, Division of Hematology/Oncology, Mayo Clinic Jacksonville, Florida


Dr. Perez is a board-certified internist, hematologist, and oncologist. She is the co-chair of the Cancer Committee at the Mayo Clinic in Jacksonville, Florida, and chair of the Breast Committee, North Central Cancer Treatment Group (NCCTG). From 1992 to 1995, she was the director of the Medical Breast Cancer Clinic at the School of Medicine, University of California, Davis, where she also taught in the department of Internal Medicine’s division of Hematology and Oncology. She recently served as a member of the Breast Cancer Committee (SWOG), and was on the advisory board of the SOS Breast Cancer Support Group. Her many honors and awards include The Breast Cancer Research Foundation’s Research Grant Award, and the American Association for Cancer Research’s NCI Travel Award. She was in active military duty during the Persian Gulf crisis from 1989 to 1990. She is currently working on the development of a breast screening and education program in a medically under-served population and serves as the principal investigator for many studies, including the MCJ 96-01 Phase I trial of paclitaxel, cisplatin, and topotecan in adult patients with advanced malignancies, the Mayo Clinic Women's Cancer Program Familial Cancer Project, and a number of phase II studies for different drug treatments on women with metastatic breast cancer. Dr. Perez is a manuscript reviewer for many prestigious cancer journals, including the American Journal of Surgery, Cancer, Cancer Chemotherapy and Pharmacology, Cancer Investigation, Critical Reviews Hematology-Oncology, Journal of Clinical Oncology, Mayo Clinic Proceedings, and The American Journal of Managed Care. She has received numerous grants from major pharmaceutical companies, including The Breast Cancer Research Foundation, Bristol-Myers Squibb, and Smith Kline Beecham. She is widely published in leading medical journals.

---

Mack Roach, III, M.D., Emeritus Board Member - Prostate Cancer, Bladder Cancer
Associate Professor in Residence, Department of Radiation Oncology,
University of California, San Francisco

Dr. Roach is an Associate Professor of Radiation Oncology at the University of California, San Francisco (UCSF), and also holds a position as an associate professor in the Department of Medicine, Division of Medical Oncology, with UCSF. He is a diplomat-certified internist and medical oncologist and a board-certified radiologist. Dr. Roach is the lead author of the American College of Radiology’s Guidelines for Treatment Planning, a publication prepared by the Appropriateness Criteria Committee American College of Radiology. This committee was responsible for defining how patients should be treated for prostate cancer in the U.S. Dr. Roach currently serves on the task forces of the National Cancer Institute’s Concept Evaluation Panel Committee for Prostate Cancer and the Intensity Modulated Radiation Therapy Working Group. He is chief editor of the InterNet Journal Club: Genitourninary Topics, and is active on the editorial boards of The Prostate Journal and the International Journal Radiation Oncology Bio- Physics. Dr. Roach has received significant grants from the National Institutes of Health for prostate cancer radiotherapy trials and from the American Cancer Society for clinical oncology, and was recently recognized for his work by the Best Doctors in the Bay Area and Best Doctors in America awards program. He serves on many committees and has authored more than sixty peer-reviewed articles on the topic of radiation therapy, prostate cancer, and lung cancer.

---

Mika Sinanan, M.D., PhD. - Colorectal Cancer, Pancreatic Cancer
Professor of Surgery, University of Washington School of Medicine, Seattle, WA; Associate Director, Institute for Surgical and Interventional Simulation , Medical Director, Surgical Specialties Clinic at the University of Washington Medical Center, Seattle, WA

Dr. Sinanan earned his doctor of medicine degree from Johns Hopkins University in 1980 and earned a PhD. in gastrointestinal physiology at the University of British Columbia in 1991. He completed his General Surgery training at the University of Washington in 1988.

He joined the University of Washington faculty in 1988 and has served in a variety of faculty positions since that time, rising to Professor of Surgery. He has also recently been appointed to the post of Associate Administrator for Quality and Special Projects at the University of Washington Medical Center.

In 1990, Dr. Sinanan recognized the potential for laparoscopic surgery within general surgery and led the first laparoscopic course at the University of Washington Medical Center (UWMC). He spearheaded the development of the earliest accreditation documents for laparoscopic procedures at the UW Medical Center. These early stages of activity resulted in the creation of the Center for Videoendoscopic Surgery (CVES) and Dr. Sinanan's appointment as co-director in 1995 through 2004.

In addition to a practice dealing with reoperative GI surgery, benign and malignant diseases of the hepatobiliary, pancreatic, and colorectal systems and advanced videoendoscopy, Dr. Sinanan holds a joint appointment in Electrical Engineering and has an active research program in advanced surgical technology, robotics, and simulation. His current efforts include the further development of a multi-disciplinary surgical simulation program and the study of the forces during surgical tissue-instrument interactions, funded by governmental sources for national distribution. These studies may find application in a new generation of robotic, intelligent surgical tools and have been extensively documented in national presentations and the medical literature.

Dr. Sinanan has trained his colleagues at the Puget Sound Veterans Administration Health Care System, Harborview Medical Center, Children's Hospital and Medical Center, and UWMC in laparoscopic techniques and is now focusing his energies revising the technical surgical curriculum for resident training. He has pioneered this field to the level of physician expert and become the "Teacher to the teachers," helping to train faculty throughout the University of Washington system in advanced laparoscopic techniques.

---

Walter Stadler, M.D., F.A.C.P. - Kidney Cancer, Testicular Cancer, Bladder Cancer, Prostate Cancer
Professor, Director of Genitourinary Oncology, University of Chicago, Departments of Medicine & Surgery, Sections of Hematology/Oncology and Urology

Dr. Stadler received his undergraduate degree from the University of Illinois and his M.D. from Yale University School of Medicine. He received postgraduate training at Michael Reese Hospital and Medical Center as well as the University of Chicago. He is a medical oncologist whose research focuses on novel therapeutic approaches to genitourinary malignancies. He serves as associate director of the Genitourinary Research Program, Cancer Research Program, is chair of the University of Chicago Clinical Trials Review Committee, and is the renal cell cancer cadre leader for Genitourinary Cancer Committee within the Cancer and Leukemia Group B. He has over 100 publications in this area and serves as a reviewer for a broad range of oncology journals. He is an active member of a number of cancer and urology related societies including American Society of Clinical Oncology, American Urology Association, American Association for Cancer Research, and Society for Basic Urologic Research. His work has been supported by a number of agencies and societies including the American Cancer Society, the National Institute of Health, and the Kidney Cancer Association and he serves on various peer review committees. He continues as principal investigator on a number of bladder, kidney, and prostate investigative protocols and is a sought after lecturer on therapeutic aspects of these malignancies

---

Patrick S. Swift, M.D. - Small Cell Lung Cancer, Colorectal Cancer, Prostate Cancer
Medical Director, Radiation Oncology, Alta Bates Comprehensive Cancer Center, Berkeley, Calif.

Dr. Swift has extensive experience in radiation oncology and is widely recognized by his peers for his expertise having published widely in scientific journals and contributed to more than a dozen books. He has been invited by more than 70 scientific and lay organizations to speak on brachytherapy and pelvic cancers. He is also a frequent speaker sought after by community organizations with interests in AIDS and cancer. His research interests include prostate, pediatric, and HIV-related malignancies and brachytherapy.

Dr. Swift earned his medical doctorate at the University of Pennsylvania in 1984 and completed his internship at St. Mary's Hospital and Medical Center, San Francisco in 1985 and his residency at the University of California, Department of Radiation Oncology, San Francisco. He served a fellowship at the University of California at San Francisco, and served as chief resident at the University of California, Department of Oncology.

His many honors include membership in Phi Beta Kappa, and an American Cancer Society Clinical Fellowship, 1987-1988. Dr. Swift was named to the list of "Best Physicians in Northern California" compiled by San Francisco Focus Magazine, April 1999.

He is a member of the American Society of Therapeutic Radiation Oncologists, the American College of Radiology and the American Society of Clinical Oncology among many others. Dr. Swift is certified by the American Board of Radiology, Therapeutic, and is an invited examiner for the oral boards in radiation oncology.

---

Ashutosh Tewari, MD, M.Ch., Emeritus Board Member - Bladder Cancer, Testicular Cancer, Kidney Cancer
Director Robotic Prostatectomy and Urologic Oncology Outcomes Weill Medical College of Cornell University

Dr. Tewari is an expert in urological diseases, specifically prostate cancer and benign prostatic hyperplasia. Appointed in 1998 as the Josephine Ford Urologic Oncology Scholar at the Henry Ford Hospital in Detroit, Michigan, Dr. Tewari is internationally recognized in the medical scientific community.

Dr. Tewari recently joined the Cornell Institute of Robotic Surgery in the Department of Urology- Robotic Prostatectomy program at New York Presbyterian Hospital at New York Weill Cornell Medical Center. He is one of the world's leading experts on robotic prostatectomy. He has been involved in more than 800 robotic surgery cases and gives instructional courses on robotics during American Urological Association meetings and has presented multiple papers on prostate cancer and robotics during various national and international meetings.

Dr. Tewari has won several awards in national and international forums and has authored or co-authored more than 50 peer-reviewed articles. His work involving prostate cancer outcome prediction using artificial intelligence-based neural networks has received widespread recognition and has been honored by the American Urological Association. He has been named Fellow in Uro-Oncology Prostatic Diseases and Lasers at the Shand’s Hospital, V.A.M.C., University of Florida, Gainsville. He is also a Fellow at the V.A.M.C., U.C. San Francisco. As an entrepreneur, Dr. Tewari has been instrumental in creating an international healthcare delivery company, which is currently establishing uro-renal hospitals in Asia.

---

James Tate Thigpen, M.D. - Ovarian Cancer, Uterine Cancer, Cervical Cancer
Professor of Medicine and Director of the Division of Medical Oncology, University of Mississippi Medical Center

As group vice chairman for science for the Gynecologic Oncology Group, and as a member of the Southwest Oncology Group, two of the largest clinical trials cooperatives in the United States, Dr. Tate Thigpen plays a key role in the organization of clinical trials for new agents in the treatment of gynecologic cancer. Over his 30-year career, Dr. Thigpen has focused his clinical research on improving treatment and survival for gynecologic cancers. During that time, he has co-authored more than 170 research papers, and given scientific presentations at more than 45 international meetings, 170 national meetings and 154 regional meetings. He has served as one of two group vice chairs and on several committees of the Gynecologic Oncology Group since 1978 and served on the Sarcoma and GYN Committee of the Southwest Oncology Group since 1973.

Dr. Thigpen has also served on a variety of committees for the National Cancer Institute, chairing the Cancer Clinical Investigators Review Committee from 1993 to 1995. He has also served on various committees of the American Society of Clinical Oncology. He sits on the editorial boards of Gynecologic Oncology, the Journal of Biologic Response Modifiers, the Journal of the National Cancer Institute and the Journal of Clinical Oncology. He also reviews research articles for the Annals of Internal Medicine, Cancer and the New England Journal of Medicine among others.

Among his many honors, Dr. Thigpen is listed in Who's Who in Frontier Science and Technology, Who's Who in Cancer: Professionals and Facilities, Who's Who in the World and is regularly included in the physician survey of Best Doctors in America. He is a fellow in the American College of Physicians, and was named Distinguished Southern Oncologist by the Southern Association of Oncology in 1995. He is also a member of the Alpha Omega Alpha Medical Honor Society.

Dr. Thigpen has been certified by the American Board of Internal Medicine since 1972 and is board certified in subspecialties for hematology and oncology. He is an active member of the American Society of Oncology, the Society of Gynecologic Oncologists and the American Association for Cancer Research.

---

John Thompson, M.D. - Melanoma, Kidney Cancer
Co-director, University of Washington Melanoma Clinic; Professor of Medicine, Division of Oncology University of Washington School of Medicine; Member, Fred Hutchinson Cancer Research Center.

Dr. Thompson's clinical and laboratory research interest focuses on discovering more effective ways to harness the immune system to prevent or treat cancer. Current research projects include the development of interleukins and interferons, cancer vaccines, stem cell transplantation and gene therapy for treating melanoma and renal cell (kidney) cancer.

He has co-authored 95 research papers, eight book chapters and dozens of other publications and abstracts on cancer.

Thompson completed his undergraduate work at Davidson College, Davidson, NC, and earned his M.D. at the University of Alabama, Birmingham in 1979. He completed his internship and residency in internal medicine at the University of Washington, Seattle, WA. Thompson completed an oncology fellowship at the University of Washington in 1985.

Thompson currently serves as a member of the medical advisory board for the National Kidney Cancer Association, the National Comprehensive Cancer Network, and the melanoma subcommittee of the American Joint Commission on Cancer. He also is a member of the American Society of Clinical Oncology (ASCO), the American Association for Cancer Research, the Southwest Oncology Group, and the American Society of Gene Therapy, among others. He served as president of the Washington State Medical Oncology Society in 1996-1997, and currently serves as secretary treasurer of the group. Thompson is an ad hoc reviewer for Journal of Clinical Oncology, Cancer Research, Journal of Immunotherapy and Blood.

Thompson sits on the editorial boards of the Hematopoietic Index and Reviews, and serves as the online news coordinator for ASCO and ad hoc reviewer for Cancer Research and Blood.

His many honors include the National Cancer Institute's Clinical Investigator Award and election to the Alpha Omega Alpha Medical Honor Society.

---

Dianne B. Thompson, M.D. - Melanoma
Dermatologist, Northwest Skin Specialists

Dr. Thompson is a practicing dermatologist in Seattle with a research background in the development of immunotherapy for cancer. Her current clinical research interests include immunotherapy for psoriasis and atopic dermatitis. During her training she collaborated with colleagues at the University of Washington and Fred Hutchinson Cancer Research Center on research into therapy for chronic graft-versus-host-disease in marrow transplant patients and the development of cultured T-cells that specifically target tumor antigens.

Dr. Thompson did her undergraduate work at the University of Idaho and earned her M.D. at the University of Washington in 1990. She completed her training at the University of Washington with a residency in Internal Medicine at the UW and then went on to an oncology clinical fellowship at the Hutchinson Center. She served as chief resident in Dermatology at the UW from 1995 to 1996, and she was named one of "Seattle's Top Doctors" in the 2005 and 2006 survey.

She is board certified by the American Board of Dermatology; a member of the American Academy of Dermatology, King County Medical Society, Washington State Dermatology Association, Seattle Dermatologic Society, and the American Society of Cosmetic Dermatology and Aesthetic Surgery.

---

Erik L. Torgerson, M.D. - Testicular Cancer, Prostate Cancer, Kidney Cancer, Bladder Cancer
Urologist, Swedish Urology Group, Swedish Medical Center

Education
Medical School: Baylor College of Medicine
Residency: University of California at Los Angeles, CA
Additional Qualifications: Internship University of California at Los Angeles, CA

Board Certification
Urology

Clinical Interests/Special Procedures Performed
Endourology, Erectile Dysfunction, Female Urology, Infertility, Nephrolithinsis, Urinary Incontinence, Urologic Oncology, Vasectomy

Philosophy of Care
My practice philosophy is that patients should play an integral role in the doctor-patient relationship. I believe patients should make treatment decisions based on the facilitation and education provided by their physician. Because I value my patients' time and effort in visiting me, I make every effort to see them in a timely manner, often the same week of their request. Professional Organizations
King County Medical Society
American Urological Association
Washington State Medical Association
Washington State Urology Society
Northwest Urological Society

Awards and Honors
Seattle Best Doctors, 2004 Seattle Magazine Seattle Best Doctors, 2006 and 2007 Seattle Metropolitan Magazine

---

Alan Venook, M.D. - Colorectal Cancer, Pancreatic Cancer
Chief, Section of Gastrointestinal Oncology, Division of Hematology and Oncology, Department of Medicine, Cancer Research Institute, University of California, San Francisco (UCSF)

Dr. Venook is a board-certified medical oncologist and hematologist. He serves as the Chief of the Section of Gastrointestinal Oncology and as an Associate Professor of Clinical Medicine in the Division of Hematology and Oncology, Department of Medicine at the University of California at San Francisco’s (UCSF) Cancer Research Institute. He also directs the Clinical Research Office at UCSF/Mt. Zion Cancer Center. Dr. Venook is the Principal Investigator on two projects: the National Surgical Adjuvant Breast and Bowel Project, and Cancer and Leukemia Group B. He serves on a number of medical boards, including the Board of Directors of the American Cancer Society in San Francisco, and the PDQ Adult Treatment Advisory Editorial Board, National Cancer Institute. He is also on the Guidelines Committee of the National Comprehensive Cancer Network for hepatobiliary cancer and colorectal cancer. He is on the editorial boards of Medscape Oncology and Cancer Therapeutics and is on the ad hoc editorial review boards for the New England Journal of Medicine, Journal of Clinical Oncology, American Journal of Gastroenterology, Gastroenterology, Cancer Research, Annals of Internal Medicine, and others. He has published widely on the topic of gastrointestinal cancer, colorectal cancer, and cancer chemotherapy in general.

---

Nicholas J. Vogelzang, M.D., Emeritus Board Member - Testicular Cancer, Kidney Cancer, Prostate Cancer, Bladder Cancer
Director, Nevada Cancer Institute

Dr. Vogelzang is a world-renowned medical oncologist and internist. Named director of the newly established Nevada Cancer Institute scheduled to open in 2005, Vogelzang formerly directed the University of Chicago’s Cancer Research Center and department of Genitourinary Oncology. Dr. Vogelzang is an active member in a number of important medical societies, including the American Urological Association, the Society of Urologic Oncology, and the American Society of Clinical Oncology. He has served on dozens of local and national committees under the auspices of the National Cancer Institute (NCI), the American Society of Clinical Oncology (ASCO), the American Cancer Society (ACS), the American Association for Cancer Research (AACR), and the Cancer and Leukemia Group B (CALGB), to name a few. Dr. Volgelzang was most recently elected to the board of directors of the Association of American Cancer Institutes. He also is a committee member for the National Cancer Institute Study Section H of the NIH/NCI, and serves on the advisory boards of the Cancer Wellness Center in Skokie, IL, and the Wellness House in Hinsdale, IL. He is a reviewer for many medical journals, including: New England Journal of Medicine, Journal of the American Medical Association, Cancer, Cancer Investigation, Cancer Research, Journal of Clinical Oncology, Journal of National Cancer Institute, Journal of Urology, Urology, and Prostate. He is on the Medical Advisory Board of US Too, 2000, and is on the editorial boards of One – Oncology Economics, Cancer Research, Cancer, The Prostate Journal, New Developments in Prostate Cancer Treatment, Seminars in Oncology, Journal of Clinical Oncology, and others. Dr. Vogelzang has received many honors and awards, most recently receiving the 1999 American Cancer Society St. George National Award and the Fred C. Buffett Chair in Genitourinary Oncology. He has won numerous grants and contracts, from organizations such as Abbott Laboratories, Lilly Research Laboratories, and NIH/NCI, for his groundbreaking cancer research. His work has been published in nearly 200 articles in leading medical journals, and he has lectured widely on the topic of cancer treatment, giving a number of talks on prostate cancer and bladder cancer.

---

Everett E. Vokes, M.D., Emeritus Board Member - Head and Neck Cancers
Director, Section of Hematology-Oncology, University of Chicago School of Medicine; Co-Director Program in Clinical and Experimental Therapeutics, Duchossois Professor, Chicago Pritzker School of Medicine, University of Chicago

Dr. Vokes's current research interests focuses on advancing the state of available therapies for patients with oral and lung cancers. As principal investigator for a pair of major NCI program projects, he oversees the design, development and implementation of phase II clinical trials investigating anti-cancer agents. The trials investigate multiple modes of cancer treatment for head and neck, and lung cancers.

Born in the United States, he grew up in Germany where he earned his doctor of medicine degree from the University of Bonn Medical School. He continued his medical training at St. Luke's Hospital in Sydney, Australia and completed an internship in internal medicine, surgery and obstetrics and gynecology at the Malteser Hospital in Bonn. He completed his fellowship in hematology and oncology at the University of Chicago School of Medicine.

He has since served in numerous capacities at the University of Chicago including director of the Head and Neck Oncology Program, program director for Clinical Investigations, core director of Biostatistics and Data Management, chair of the Clinical Trials Review Committee and associate director (clinical affairs), University of Chicago Cancer Research Center.

Dr. Vokes serves on numerous national and international committees including the American Association of Cancer Researcher fellowship committee and the National Cancer Institute Cancer Center Review Committee.

He serves as a reviewer for many scientific journals including the New England Journal of Medicine, The Lancet, Journal of Clinical Oncology and Journal of the National Cancer Institute among others.

Among his many honors he is a member of the American Society of Clinical Investigation and is regularly listed among America's best cancer doctors by several publications.

---

William C. Wood, M.D. - Breast Cancer
Chief of Surgery, Emory University Hospital; Whitehead Professor and Chairman, Department of Surgery, Emory University School of Medicine; Clinical Director, Winship Cancer Institute, Atlanta, Ga.

As chair of surgery since 1991, Dr. Wood oversees the clinical and research programs of the Department of Surgery. He also heads the Breast Cancer Program of the Winship Cancer Institute at Emory University School of Medicine. His current research interests focus on improving disease-free and overall-survival in breast cancer patients.

Having published more than 250 research studies over the past 30 years, Dr. Wood has been a major influence on national and international trends in cancer therapy. He served as chairman of the 1990 National Institutes of Health Consensus Development Conference on Management of Early Breast Cancer, and for 10 years chaired the Breast Cancer Committee of the Cancer and Leukemia Group B, a NIH cooperative group of 21 major cancer centers committed to cooperative research and clinical trials, and for eight years chaired the Breast Cancer Committee of the Eastern Cooperative Oncology Group.

Before joining Emory University Medical School, he served as both the medical director of the cancer center and chief of surgical oncology at Massachusetts General Hospital, Boston, MA.

Dr. Wood also has served on numerous national oncology committees and is currently president of the Society of Surgical Oncology. He is a member of the board of governors for the American College of Surgeons. Dr. Wood is a member of the medical advisory board for the National Alliance of Breast Cancer Organizations; and chairs the NIH/NCI Clinical Trials Cooperative Groups Breast Intergroup Committee and co-chairs the Early Breast Cancer Trialists’ Collaborative Group, Oxford, United Kingdom.

Dr. Wood earned his medical doctorate from Harvard Medical School in 1966 and completed his internship at Massachusetts General Hospital, where he also served as assistant and chief resident in surgery. He completed fellowship training at the National Institutes of Health and Harvard Medical School.

He is a member of numerous editorial boards and professional societies. Dr. Wood is an editor-in-chief of Oncology and associate editor of the American Journal of Clinical Oncology. He serves as a member of the American Association for Cancer Research, the American Association of Immunologists, American College of Surgeons and American Society of Clinical Oncology (ASCO), among many others.

---

Hadi Yaziji, M.D. Member Emeritus, Medical Editorial Board - All Cancer Tools
Founder and president of Ancillary Pathways, LLC

Dr. Yaziji is an internationally recognized pathologist serving as assistant clinical professor at University of British Columbia and adjunct assistant professor at University of Texas, MD Anderson Cancer Center. He previously worked at PhenoPath Laboratories from 1996 to 2004, and subsequently served as the director of Molecular Oncodiagnostics Laboratories, Baptist Hospital of Miami. Dr. Yaziji’s contributions to the oncology community include his research in the translational applications of Immunohistochemistry, FISH and ancillary pathology in the diagnosis and work-up of cancer. He published dozens of peer-reviewed scientific articles that deal with various topics of applied immunohistochemistry, including HER-2 testing by FISH. He is a regular speaker at national and international pathology meetings.

---